761 Stock Chart & Stats
€80.60
-€0.50(-0.61%)
At close: 4:00 PM EDT
€80.60
-€0.50(-0.61%)
Day’s Range― - ―
52-Week Range€38.55 - €94.00
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€800.62M
Enterprise Value€743.54
Total Cash (Recent Filing)€29.00M
Total Debt (Recent Filing)€19.10M
Price to Earnings (P/E)37.3
Beta0.39
Next Earnings
Sep 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.22
Shares Outstanding9,680,977
10 Day Avg. Volume7
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.58
Revenue Forecast (FY)€154.59M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthThe multi-year increase in revenue indicates continued product adoption and channel expansion. Sustaining growth across pharmacy, healthcare-professional and international distribution channels can support scale and reinforce PharmaNutra’s market position.
Improving Balance SheetLower debt and a moderate debt-to-equity ratio improve financial resilience and reduce balance-sheet pressure. Continued equity growth also provides capacity to fund product development, international expansion and working-capital needs.
Strong Operating Cash GenerationConsistently positive operating cash flow and solid recent free cash flow show that the business can convert operations into funding. This supports reinvestment and financial flexibility without relying heavily on external capital.
Bears Say
Sharp Operating Profitability DeteriorationThe shift to negative TTM operating profit and EBITDA raises a fundamental concern about earnings quality. If persistent, it could weaken the profitability of the core product portfolio and limit the benefit of continued revenue growth.
Volatile Gross MarginsUnstable gross margins make future earnings less predictable and may indicate changing product mix, input costs or commercial conditions. This reduces confidence that historical margins can be maintained as the company expands.
Uneven Free Cash Flow ConversionAlthough recent cash generation is positive, the historical volatility and incomplete conversion from net income indicate working-capital or investment demands. This could constrain internally funded growth if operating profitability remains weak.
PharmaNutra SpA News
761 FAQ
What was PharmaNutra SpA’s price range in the past 12 months?
PharmaNutra SpA lowest stock price was €38.55 and its highest was €94.00 in the past 12 months.
What is PharmaNutra SpA’s market cap?
PharmaNutra SpA’s market cap is €800.62M.
When is PharmaNutra SpA’s upcoming earnings report date?
PharmaNutra SpA’s upcoming earnings report date is Sep 11, 2026 which is in 2 days.
How were PharmaNutra SpA’s earnings last quarter?
PharmaNutra SpA released its earnings results on May 11, 2026. The company reported €0.36 earnings per share for the quarter.
Is PharmaNutra SpA overvalued?
According to Wall Street analysts PharmaNutra SpA’s price is currently Overvalued.
Does PharmaNutra SpA pay dividends?
PharmaNutra SpA does not currently pay dividends.
What is PharmaNutra SpA’s EPS estimate?
PharmaNutra SpA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaNutra SpA have?
PharmaNutra SpA has 9,680,977 shares outstanding.
What happened to PharmaNutra SpA’s price movement after its last earnings report?
PharmaNutra SpA reported an EPS of €0.36 in its last earnings report. Following the earnings report the stock price went up 0.783%.
Which hedge fund is a major shareholder of PharmaNutra SpA?
Currently, no hedge funds are holding shares in DE:761
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaNutra SpA
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
Technical Analysis
Garofalo Health Care S.P.A.
―
Arterra Bioscience SpA
―
Eukedos S.p.A.
―
Farmacosmo S.P.A.
―
Svas Biosana S.p.A.
―